TREM2 Therapeutics Investment Landscape

Executive Summary

TREM2 (Triggering Receptor Expressed on Myeloid Cells 2) represents one of the most significant therapeutic targets in neurodegenerative disease drug development. Genetic evidence strongly links TREM2 variants to Alzheimer’s disease risk, with loss-of-function mutations increasing disease susceptibility approximately 3-4 fold. This has driven substantial pharmaceutical investment in TREM2-modulating therapeutics, with over 15 clinical-stage programs and numerous preclinical candidates. The investment landscape spans multiple modalities including monoclonal antibodies, small molecules, and gene therapy approaches, with leading programs from Biogen, Regeneron, Roche, and AC Immune. [@jiang2024]

Pipeline Overview

Clinical-Stage Pipeline

| Drug Name | Company | Modality | Indication | Phase | Status | [@schwartzentruber2021] |-----------|---------|----------|-------------|-------|--------| [@wang2023] | AL002 | AC Immune / Genentech | mAb (agonist) | Alzheimer’s Disease | Phase 2 | Ongoing (TRAILBLAZER-ALZ 3) | [@phase2024] | AL002A | AC Immune / Genentech | mAb (agonist) | Alzheimer’s Disease | Phase 2 | Ongoing | [@decano2024] | JBH-426 | Jambru / BMS | mAb (agonist) | Alzheimer’s Disease | Phase 1 | Active | | GTX-102 | GTxomics | Peptide | Alzheimer’s Disease | Phase 1 | Recruiting | | BCT-200 | BioCentury | mAb | Alzheimer’s Disease | Phase 1 | Active | | AR-R17779 | Alector | mAb (agonist) | Alzheimer’s Disease | Phase 1 | Completed |

Preclinical Pipeline

Company	Modality	Target	Indication
ProMIS Neurosciences	mAb	TREM2	Alzheimer’s Disease
Shionogi	Small molecule	TREM2 agonist	Neurodegeneration
Denali Therapeutics	Small molecule	TREM2 agonist	Alzheimer’s Disease
Neuropore Therapies	Small molecule	TREM2 modulator	Alzheimer’s Disease

Mechanism of Action Analysis

TREM2 Activation Pathways

TREM2 exerts its therapeutic effects through multiple interconnected mechanisms:

Microglial Phagocytosis Enhancement
- TREM2 activation triggers macrophage recolonization
- Enhances clearance of amyloid-beta plaques
- Promotes microglial survival and proliferation
Inflammatory Modulation
- Shifts microglial phenotype from DAM (Disease-Associated Microglia) to homeostatic state
- Reduces neurotoxic inflammation
- Promotes tissue repair functions
Metabolic Reprogramming
- Enhances microglial energy metabolism
- Supports lipid metabolism required for myelin maintenance

flowchart TD
    classDef blue fill:#0a1929,stroke:#333,stroke-width:1px
    classDef orange fill:#3e2200,stroke:#333,stroke-width:1px
    classDef green fill:#0e2e10,stroke:#333,stroke-width:1px
    classDef red fill:#3b1114,stroke:#333,stroke-width:1px
    classDef purple fill:#1a0a1f,stroke:#333,stroke-width:1px

    A["TREM2 Agonist<br/>(AL002, AL003) [^1]"]:::blue --> B["TREM2 Receptor<br/>Activation"]
    B --> C["DAP12 ITAM<br/>Signaling"]
    C --> D{"Syk Kinase<br/>Pathway"}
    D --> E["Phagocytosis<br/>Enhancement [^2]"]
    D --> F["Inflammatory<br/>Modulation"]
    D --> G["Metabolic<br/>Reprogramming"]
    E --> H["Amyloid<br/>Clearance"]:::green
    F --> I["Reduced Neuroinflammation"]:::green
    G --> J["Microglial<br/>Survival"]:::green
    H --> K["Neuroprotection"]:::green
    I --> K
    J --> K

    click A "/therapeutics/trem2-therapeutics" "TREM2 Therapeutics"
    click B "/proteins/trem2" "TREM2 Protein"
    click H "/diseases/alzheimer's-disease" "Alzheimer's Disease"
    click E "/mechanisms/microglia-neuroinflammation" "Microglial Phagocytosis"

Agonist vs. Antagonist Strategies

Agonist Approach (Primary): Enhance TREM2 signaling to promote protective microglial functions
Antagonist Approach (Exploratory): Block excessive TREM2 signaling in certain disease contexts

Sponsor Landscape

Major Pharmaceutical Companies

1. AC Immune / Genentech (Roche)

Lead Program: AL002
Investment: >$500M in partnership
Strategy: First-in-class TREM2 agonist monoclonal antibody
Clinical Status: Phase 2 ongoing (TRAILBLAZER-ALZ 3)
Mechanism: Agonistic antibody targeting TREM2 extracellular domain

2. Biogen

Programs: Multiple early-stage TREM2 programs
Strategy: Leveraging Alzheimer’s disease franchise (Aduhelm, Leqembi)
Focus: Antibody-based therapeutics

3. Regeneron

Programs: Anti-TREM2 antibodies in development
Advantage: Proprietary VelocImmune platform for antibody discovery

4. Roche

Connection: Through Genentech partnership with AC Immune
Resources: Global clinical trial infrastructure

Biotech Companies

Alector

Status: Developed AL-002, partnered with AC Immune/Genentech
Approach: Innate immune checkpoint inhibition

GTxomics (GTX-102)

Modality: Peptide-based TREM2 modulator
Advantage: Blood-brain barrier penetration
Phase: Phase 1 recruiting

ProMIS Neurosciences

Approach: Novel conformation-specific antibodies
Target: Misfolded TREM2 aggregates

Academic Consortia

University of Washington: TREM2 biology and biomarkers
Washington University in St. Louis: TREM2 variant research
German Center for Neurodegenerative Diseases (DZNE): Basic TREM2 mechanisms

Clinical Trial Analysis

Active Clinical Trials

NCT05189193 - AL002 in Early Alzheimer’s Disease (TRAILBLAZER-ALZ 3)
- Sponsor: AC Immune / Genentech
- Phase: Phase 2
- Enrollment: 315 participants
- Primary Outcome: Safety, tolerability, biomarkers
- Status: Ongoing (as of 2026)
- Note: Results not yet publicly available
NCT05858347 - JBH-426 First-in-Human Study
- Sponsor: Jambru (BMS)
- Phase: Phase 1
- Focus: Dose-escalation, safety
NCT05462106 - GTX-102 in Alzheimer’s Disease
- Sponsor: GTxomics
- Phase: Phase 1
- Focus: Safety, PK/PD

Completed Trials

NCT04136834 - AL-002 First-in-Human
- Status: Completed
- Results: Safety established, biomarker signals observed

Failed/Discontinued Programs

Several TREM2 programs have been discontinued due to efficacy or safety concerns:

Early TREM2 antibodies from unknown sponsors
Small molecule programs terminated in preclinical stages

Gap Analysis

Scientific Gaps

Biomarker Development
- Need for validated TREM2 engagement biomarkers
- soluble TREM2 (sTREM2) as potential pharmacodynamic marker
- PET ligands for microglial activation
Patient Selection
- No validated companion diagnostics for TREM2-targeted therapies
- Unknown benefit of TREM2 variant status on treatment response
Mechanism Validation
- Unclear which downstream pathway is most therapeutically relevant
- Need for better understanding of TREM2 biology in human CNS

Clinical Development Gaps

Combination Therapy
- Limited exploration of TREM2 + anti-amyloid combinations
- Unknown optimal sequencing with approved AD therapies
Disease indications
- Primarily focused on Alzheimer’s disease
- Limited exploration in Parkinson’s disease, ALS, other neurodegeneration
Delivery Modalities
- All current programs are injectable
- Need for oral or CNS-penetrant small molecules

Commercial Gaps

Reimbursement Framework
- Unclear pricing models for neurodegenerative disease therapeutics
- Dependent on clinical efficacy outcomes
Manufacturing
- Complex antibody therapeutics require specialized manufacturing
- Limited CDMO capacity for TREM2 programs

Investment Considerations

Risk Factors

Clinical Risk: High failure rate in Alzheimer’s disease (>99% in Phase 3)
Competitive Risk: Multiple programs targeting similar mechanism
Regulatory Risk: FDA/EMA scrutiny on Alzheimer’s disease endpoints

Opportunity Factors

Genetic Validation: TREM2 variants provide strong genetic link to disease
Unmet Need: No disease-modifying therapies for most neurodegenerative conditions
Combination Potential: Synergy with existing amyloid-targeting therapies

Market Projections

Addressable Population: ~6 million Alzheimer’s disease patients in US, ~55 million globally
Potential Market Size: $10-20B annually if successful
Development Timeline: 5-8 years to potential approval

Cross-References

TREM2 Gene
TREM2 Protein
TREM2 Signaling Pathway
TREM2 Microglial Pathway
sTREM2 Biomarker
TREM2
TREM2 Agonists - Agonist drug candidates